Impact Biomedical IBO

Impact Biomedical Inc. discovers, confirms, and patents unique science and technologies that can be developed into new offerings in human healthcare and wellness.
The company focuses on areas such as biopharmaceuticals, over the counter wellness products, and drug discovery for neurological, oncologic, and inflammatory conditions.
It pursues these goals through its own research and through collaborations with external partners via licensing, co development, joint ventures, and other relationships.
Impact Biomedical maintains a portfolio of proprietary platforms including Linebacker, Laetose, Functional Fragrance Formulation, and Equivir.
The firm’s mission is to advance human health by translating scientific discoveries into tangible products that address unmet medical needs.

Impact Biomedical generates revenue chiefly by licensing its patented technologies to corporate partners in exchange for upfront fees, milestone payments, and ongoing royalties.
Licensees such as ProPhase Laboratories have obtained rights to develop and commercialize the Linebacker and Equivir platforms worldwide.
The company also seeks to commercialize products directly, for example through the acquisition of the Celios Air Purification technology which can be sold to consumers and institutions.
Additional revenue may arise from future sales of Laetose as a sugar alternative, Functional Fragrance Formulations for industrial use, and other emerging technologies once they reach market.
The company also anticipates income from royalty streams once its licensed technologies achieve commercial sales by partners.

The company operates through the following segments.

• Biotechnology: This segment focuses on discovering, confirming, and patenting unique science and technologies for human healthcare and wellness, developing biopharmaceuticals, over the counter wellness products, and drug discovery for neurologic, oncologic, and inflammatory diseases through partnerships and potential direct sales while managing a growing patent portfolio that includes 60 issued and over 60 pending patents as of the end of 2025.

Impact Biomedical occupies a specialized niche within the broader biotechnology and wellness industries, competing with large pharmaceutical corporations, specialty biotech firms, academic research institutions, and government agencies.
Its competitive advantage lies in a deep pipeline of proprietary technologies supported by a substantial intellectual property base of numerous issued and pending patents.
The company leverages strategic alliances with established players such as ProPhase Laboratories and Chemia Corporation to advance development and commercialization efforts.
These partnerships enable Impact Biomedical to access manufacturing, distribution, and marketing capabilities while retaining ownership of its core innovations.
Despite being smaller than many industry incumbents, Impact Biomedical differentiates itself through its focus on naturally derived compounds and its agile partnership model.

Impact Biomedical serves primarily corporate partners that seek to license its technologies for further development and commercialization.
Current licensees include ProPhase Laboratories, which holds worldwide rights to the Linebacker and Equivir platforms, and Chemia Corporation, which collaborates on the Functional Fragrance Formulation.
The company also engages with pharmaceutical companies, consumer packaged goods manufacturers, and other potential partners that may adopt its sugar alternative Laetose or its air purification technology.
While most revenue comes from these business to business relationships, future direct to consumer sales could expand the customer base to include individual consumers and healthcare providers.
Impact Biomedical maintains active discussions with multiple firms to expand its licensing network and explore joint ventures for new product development.